Bioorganic & Medicinal Chemistry Letters Volume 22, Issue 21, 2012 Contents BMCL REVIEW How hydrogen bonds impact P-glycoprotein transport and permeability pp 6540–6548 Prashant V. Desai, Thomas J. Raub, Maria-Jesus Blanco* 1 F F NH N H R O O O O 1 F F NH N H R O O O O O O N N NH 2 O H O O N N NH2 O H REGULAR ARTICLES Design, synthesis and biological activities of sorafenib derivatives as antitumor agents pp 6549–6553 Jianwen Yao, Zuopeng He, Jing Chen, Wei Sun, Hao Fang, Wenfang Xu* H N H N S N R O O Ar Twenty three new sorafenib derivatives 9a–9w have been prepared and evaluated for their anticancer activity. Identification of a novel and orally available benzimidazole derivative as an NPY Y5 receptor antagonist with in vivo efficacy pp 6554–6558 Yuusuke Tamura*, Naoki Omori, Naoki Kouyama, Yuji Nishiura, Kyouhei Hayashi, Kana Watanabe, Yukari Tanaka, Takeshi Chiba, Hideo Yukioka, Hiroki Sato, Takayuki Okuno N H N N S O O O Ph 8b Y5IC 50 = 0.43 nM Bioorganic & Medicinal Chemistry Letters 22 (2012) 6527–6539 Contents lists available at SciVerse ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl
Novel synthetic heteroretinoid (4) and its amide derivatives (5a–j) were synthesized and have shown significant in vivo antileishmanial activity against Leishmania donovani inhamsters.
Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of themetalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR)
pp 6563–6567
Catherine Zinglé, Lionel Kuntz, Denis Tritsch, Catherine Grosdemange-Billiard*, Michel Rohmer*
OHHO P(O)(OH)2n
7a n=17b n=2
HOPO
Nn
9a n = 19b n = 2
S
S
NaO
Na
(HO)2(O)PNHn
8a n = 18b n = 2
S
S(HO)2(O)P
NH
ONH2
10 11 R = H12 R = Me
(HO)2(O)PNR
OO
A hierarchical method for molecular docking using cloud computing pp 6568–6572
Ling Kang, Quan Guo, Xicheng Wang*
Design, synthesis, and structure–activity-relationship of phenyl imidazoles as potent Smoothenedantagonists
pp 6573–6576
Dai Cheng, Dong Han, Wenqi Gao, Qihui Jing, Jiqing Jiang, Yongqin Wan, Nathan P. Englund, Tove Tuntland, Xu Wu,Shifeng Pan*
NH
Cl
N NH
N
OOCH3
OCH3
HhAntag691
NH
Cl
N NH
N
N
NO
Compound 19
6528 Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539
Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated bypolymeric amphiphiles
pp 6577–6579
María L. Cuestas, Amalia I. Castillo, Alejandro Sosnik, Verónica L. Mathet*
abcg2 mRNA
mrp1 mRNA
mdr1 mRNA
qPCR
Formylated polyamines as peptidomimetics pp 6580–6582
Sacha Javor, Aaron Janowsky, Robert Johnson, Katherine Wolfrum, Mitra Tadayoni-Rebek*, Julius Rebek Jr.*
Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation pp 6583–6586
Yanhui Yang, Andrew Voak, Shane R. Wilkinson, Longqin Hu*
HO NH2
O
NH2
CHF2
DFMO
O NH
O
HN
CHF2R
O
OR
O
OR
Potential DFMO Prodrugs
R =O2N H(or F)
3,30-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding pp 6587–6590
Patrick T. Weiser, Anna B. Williams, Ching-Yi Chang, Donald P. McDonnell, Robert N. Hanson*
OH
O
R
R
O O
O
O
R
R
O O
O
O
R
R
O OH
N N
6a-e 7a-e 1a-e
R = H, i-Pr, s-Bu, t-Bu, Bn
Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539 6529
Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides
pp 6591–6595
Xiu Jie Liu*, Xin Xin Shi*, Yong Liang Zhong, Ning Liu, Kai Liu
O
O ONH
NH
N N
Picotamide
1
ONH
NH
O OR R
Target Compounds
2
Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamidemoiety as potential anti-melanoma agents
Based on in silico screening results, a series of novel 3,5-diarylpyrazoline salicylamidederivatives were designed and synthesized. Compound 25 exhibited the most potent inhibitoryactivity with an IC50 value of 0.16 lM for BRAFV600E and GI50 value of 0.24 lM for mutantBRAF-dependent WM266.4 melanoma cells.
Design, synthesis, spectral and biological evaluation of novel 1-allyl substituted2,6-diphenylpiperidin-4-ones and its derivatives of oximes/oxime ethers
Reagents and Conditions :- a) NH2NH2.H2O, CH3COOH, 120 °C, 12h, b) SnCl2.H2O/EtOAc, r.t. 12h,c) Isocyanate/THF, r.t. 1-2h, d) Isothiocyanate/THF, r.t. 1-2h,e) Sulfonyl chlorides/DCM, Et3N, r.t. 1-2h.
ce
d
A novel series of 1-acetyl-3,5-diaryl-4,5-dihydro (1H) pyrazole derivatives bearing urea, thiourea and sulphonamide have been designed, synthesized andevaluated for anti-inflammatory and antimicrobial activities against pathogenic bacteria and fungi.
Novel 3-substituted-1-aryl-5-phenyl-6-anilinopyrazolo[3,4-d]pyrimidin-4-ones: Docking, synthesis andpharmacological evaluation as a potential anti-inflammatory agents
pp 6616–6620
Sandeep B. Yewale, Saurabh B. Ganorkar, Kamalkishor G. Baheti*, Rupesh U. Shelke
NN
SO OH2N
NN
NN
N
Ph
NPh
H
O
S
H
Celecoxib
CH3
FFF
CH3
O ONH2
Compound 5i
Pro A: 538
Phe B: 142
The compound 5i found to be superior to diclofenac sodium and comparable with celecoxib for anti-inflammatory activity at a dose of 25 mg/kg and showed quite lessulcerogenic potential among tested compound. The docking study revealed that compound 5i and celecoxib exhibited XP docking score )6.5485 and )5.9177, respectively.
Novel histone deacetylase 8 ligands without a zinc chelating group: Exploring an ‘upside-down’ bindingpose
pp 6621–6627
Aditya Sudheer Vaidya, Raghupathi Neelarapu, Antonett Madriaga, He Bai, Emma Mendonca, Hazem Abdelkarim,Richard B. van Breemen, Sylvie Y. Blond, Pavel A. Petukhov*
Zn+2
N3
O
NHO
HNO
N3
OH N3
O
NHO
MeO O
N3
Zn+2MeO N3
O
HN O
OO
Zn+2
UV
UV UV
+N3
Strep-HRPBT
+
BTStrep-HRP
Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors pp 6628–6631
Betty Lam*, Zhiyuan Zhang, Jeffery A. Stafford, Robert J. Skene, Lihong Shi, Stephen L. Gwaltney II
N
N
O
O N
NH2
NH2
Br
F
N
N
O
O N
NH2
N
Br
F
3nIC50 = 4.8 nM%F = 68
10eIC50 = 4.6 nM%F = 100
O
Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539 6531
Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B pp 6632–6635
Mietha M. Van der Walt, Gisella Terre’Blanche, Anél Petzer, Jacobus P. Petzer*
HN
O
O
HN
O
O
S
R
IC50(MAO-B) = 134 µM
MAO-B
R IC50 (µM)
H 0.0045
Cl 0.0056
Br 0.0074
F 0.0068
Identification of pyrimidine derivatives as hSMG-1 inhibitors pp 6636–6641
Ariamala Gopalsamy*, Eric M. Bennett, Mengxiao Shi, Wei-Guo Zhang, Joel Bard, Ker Yu
Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination ofresveratrol and decitabine
pp 6642–6646
Christine L. Clouser*, Jay Chauhan, Matthew A. Bess, Jessica L. van Oploo, Ding Zhou, Sarah Dimick-Gray, Louis M. Mansky,Steven E. Patterson*
Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity fromprotein aggregation of mutant superoxide dismutase 1
pp 6647–6650
Paul C. Trippier, Radhia Benmohamed, Donald R. Kirsch, Richard B. Silverman*
Cl
Cl
O
X X
O
R2R1
XR1 = N (alkyl, aryl, acyl, benzyl) = ActiveXR2 = NH = ActiveXR2 = CH2, O, NMe = Inactive
6532 Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethylphenylamino)pyrazin-2(1H)-one: Introduction of N3-phenylpyrazinones as potential CRF-R1 PETimaging agents
pp 6651–6655
Jeffrey A. Deskus*, Douglas D. Dischino, Ronald J. Mattson, Jonathan L. Ditta, Michael F. Parker,Derek J. Denhart, Dmitry Zuev, Hong Huang, Richard A. Hartz, Vijay T. Ahuja, Henry Wong,Gail K. Mattson, Thaddeus F. Molski, James E. Grace Jr., Larisa Zueva, Julia M. Nielsen,Heidi Dulac, Yu-Wen Li, Mary Guaraldi, Michael Azure, David Onthank, Megan Hayes, Eric Wexler,Jennifer McDonald, Nicholas J. Lodge, Joanne J. Bronson, John E. Macor N
NO
Cl
O
18
NH
OF[18F]10
Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as afunctional antagonist of the apelin (APJ) receptor
pp 6656–6660
Patrick R. Maloney, Pasha Khan, Michael Hedrick, Palak Gosalia, Monika Milewski, Linda Li, Gregory P. Roth,Eduard Sergienko, Eigo Suyama, Eliot Sugarman, Kevin Nguyen, Alka Mehta, Stefan Vasile, Ying Su, Derek Stonich,Hung Nguyen, Fu-Yue Zeng, Arianna Mangravita Novo, Michael Vicchiarelli, Jena Diwan, Thomas D.Y. Chung,Layton H. Smith, Anthony B. Pinkerton*
The recently discovered apelin/APJ system has emerged as a critical mediator of cardiovascularhomeostasis and is associated with the pathogenesis of cardiovascular disease. A role forapelin/APJ in energy metabolism and gastrointestinal function has also recently emerged. Wedisclose the discovery and characterization of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221), a potent APJ functional antagonist in cell-based assaysthat is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor.
Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confoundingeffects on in vivo and in vitro studies
pp 6661–6664
Charles J. McElhinny Jr., Anita H. Lewin*, S. Wayne Mascarella, Scott Runyon, Lawrence Brieaddy, F. Ivy Carroll
Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containingPhosphoinositide 3-kinase (PI3K) p110b isoform inhibitors through structure-based fragmentoptimisation
pp 6665–6670
Fabrizio Giordanetto*, Andreas Wållberg, Johan Cassel,Saswati Ghosal, Michael Kossenjans, Zhong-Qing Yuan,Xiaoping Wang, Lifeng Liang NH
N NO
O
NH
NH N
NO
O
NH
NH
N NO
O
N
16p110β IC50 93 nM
LE: 0.38; LLE: 4.63LogD7.4: 2.4
Solubility: 4.5 μMHLM T1/2: 41 mins
Reactive metabolites: Yes
22p110β IC50 2600 nMLE: 0.3; LLE: 4.09
LogD7.4: 1.5Solubility: >100 μM
HLM T1/2: >115 minsReactive metabolites: No
1p110β IC50 34 μM
LE: 0.38
Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539 6533
Discovery of phosphoinositide 3-kinases (PI3K) p110b isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effectiveantithrombotic agent without associated bleeding and insulin resistance
pp 6671–6676
Fabrizio Giordanetto*, Andreas Wållberg, Saswati Ghosal, Tommy Iliefski, Johan Cassel, Zhong-Qing Yuan,Henrik von Wachenfeldt, Søren M. Andersen, Tord Inghardt, Anders Tunek, Sven Nylander
NH N
NO
O
N
OH
NH
N NO
O
N
(S)-21p110β IC50 38 nMLE: 0.35; LLE: 5.5
p110α/β: 716xEC50: 1.1 μM
No HOMA increase
1p110β IC50 34 μM
LE: 0.38
Synthesis and in vitro and in vivo anticancer activity of novel 3-methyl-5H-isoxazolo[50,40:5,6]pyrido[2,3-b]indoles
pp 6677–6680
E. Rajanarendar*, K. Govardhan Reddy, S. Ramakrishna, M. Nagi Reddy, B. Shireesha, G. Durgaiah, Y.N. Reddy
ON
CH3 N NH
R
R'
7
A series of novel isoxazolo[50 ,40:5,6]pyrido[2,3-b]indoles 7 were synthesized and tested for their in vitro and in vivo anticancer activity.
Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-jB activation and PPARtranscriptional activity
pp 6681–6687
Tran Hong Quang, Nguyen Thi Thanh Ngan, Chau Van Minh, Phan Van Kiem,Pham Hai Yen, Bui Huu Tai, Nguyen Xuan Nhiem, Nguyen Phuong Thao,Hoang Le Tuan Anh, Bui Thi Thuy Luyen, Seo Young Yang, Chun Whan Choi,Young Ho Kim*
1
3
OO
OHHO
OH
OH
O
HO
HOHO
OH
OO
1
3 5
71'
4'
3' 1'' 3''
4''
HO OH
O
OH
OH
O
O
HO
HOHO
OH
1'''
5'''
3'''1''''
5''''
3'''' OH
HO
OO
HO OH
O
OH
OH
OH
O
HO
HOHO
OHOH
HO
2
Three new diarylheptanoid glycosides, plantagineosides A–C (1–3), and three knowncompounds (4–6) were isolated from the whole plant of Tacca plantaginea. Compounds 3–6significantly inhibited TNFa-induced NF-jB transcriptional activity in HepG2 cells with IC50
values ranging from 0.9 to 9.4 lM. Compounds 1–6 significantly activated the transcriptionalactivity of PPARs with EC50 values ranging from 0.30 to 10.4 lM. In addition, thetransactivational effects of compounds 1–6 were evaluated on three individual PPAR subtypes,including PPARa, c, and b(d).
The discovery of CCR3/H1 dual antagonists with reduced hERG risk pp 6688–6693
Ash Bahl, Patrick Barton, Keith Bowers, Steven Brough, Richard Evans, Christopher A. Luckhurst, Tobias Mochel,Matthew W.D. Perry*, Aaron Rigby, Robert J. Riley, Hitesh Sanganee, Adam Sisson, Brian Springthorpe
ONH
N
OCl
ClO
N
O
N SO
ON
O
Cl
ClNa
+ CCR3 pKi 8.2; H1 pKi 7.5
F (dog) free zwitterion 18%micronised sodium salt 97%
hERG pIC50<4.8
Lead : CCR3 pKi 7.0
6534 Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539
Scaffold-hopping with zwitterionic CCR3 antagonists: Identification and optimisation of a series withgood potency and pharmacokinetics leading to the discovery of AZ12436092
pp 6694–6699
Ash Bahl, Patrick Barton, Keith Bowers, Moya V. Caffrey, Rebecca Denton, Peter Gilmour, Shaun Hawley, Tero Linannen,Christopher A. Luckhurst, Tobias Mochel, Matthew W.D. Perry*, Robert J. Riley, Emma Roe, Brian Springthorpe, Linda Stein,Peter Webborn
O
NCl
Cl
N
HO O
O
NN
HO O
Cl
F
CCR3 pKi 7.4Rat t1/2 2.4 h F 13%
CCR3 pKi 9.2Rat t1/2 8.7 h F 54%
Synthesis and in vitro antitumour screening of 2-(b-DD-xylofuranosyl)thiazole-4-carboxamide and twonovel tiazofurin analogues with substituted tetrahydrofurodioxol moiety as a sugar mimic
Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitroand in vivo anti-staphylococcal activity
pp 6705–6711
Jean-Philippe Surivet*, Roland Lange, Christian Hubschwerlen, Wolfgang Keck, Jean-Luc Specklin, Daniel Ritz, Daniel Bur,Hans Locher, Peter Seiler, Daniel Stefan Strasser, Lars Prade, Christopher Kohl, Christine Schmitt, Gaëlle Chapoux, Eser Ilhan,Nadia Ekambaram, Alcibiade Athanasiou, Andreja Knezevic, Daniela Sabato, Alain Chambovey, Mika Gaertner,Michel Enderlin, Maria Boehme, Virginie Sippel, Pierre Wyss
NF3C
Br
N NH2
O
NH2
S.aureus MIC 1mg/Lin vivo efficacious
Identification of a glutathione peroxidase inhibitor that reverses resistance to anticancer drugs inhuman B-cell lymphoma cell lines
pp 6712–6715
Riad Schulz, Thomas Emmrich, Heidi Lemmerhirt, Ulrike Leffler, Kristin Sydow, Carsten Hirt, Thomas Kiefer, Andreas Link,Patrick J. Bednarski*
Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539 6535
Synthesis and evaluation of naphthoic acid derivatives as fluorescent probes to screen advancedglycation end-products breakers
pp 6716–6720
Luc Séro, François Calard, Lionel Sanguinet, Eric Levillain, Pascal Richomme, Denis Séraphin, Séverine Derbré*
Design and synthesis of potent hydroxyethylamine (HEA) BACE-1 inhibitors carrying prime side4,5,6,7-tetrahydrobenzazole and 4,5,6,7-tetrahydropyridinoazole templates
pp 6721–6727
Christian Sund, Oscar Belda, Neera Borkakoti, Jimmy Lindberg, Dean Derbyshire, Lotta Vrang,Elizabeth Hamelink, Cathrine Åhgren, Esmeralda Woestenenk, Kristina Wikström,Anders Eneroth, Erik Lindström, Genadiy Kalayanov*
WNH
HN
OR2 X Y
Z
R1 = t-but or i-pr, R 2 = (R)-OH or =O; X, Y, Z, W = C, O and/or N*R or S, or R,S-mixture
*
R1
S
Six HEA core BACE-1 inhibitors with variations on the prime side alkyl substituted 4,5,6,7-tetrahydrobenzazole and 4,5,6,7-tetrahydropyridinoazole templates were synthesized andevaluated for their BACE-1 in vitro and in vivo inhibitory activities.
Chemotherapy of leishmaniasis. Part IX: Synthesis and bioevaluation of aryl substituted ketenedithioacetals as antileishmanial agents
Using a newly developed assay method, the glycolipid Acremomannolipin A (1), isolated from the fungus Acremonium strictum, was identified as apotential calcium signal modulator. The structure of 1 is quite novel and unique, and exhibits the properties of both lipids and sugars due to thehybridization of these two types of biomolecules.
Effect of substituents at phenyl group of 7,70-dioxo-9,90-epoxylignane on antifungal activity pp 6740–6744
Synthesis and pharmacological evaluation of N-substituted 2-(2-oxo-2H-chromen-4-yloxy)propanamideas cyclooxygenase inhibitors
pp 6745–6749
D. Rambabu, Naveen Mulakayala, Ismail, K. Ravi Kumar, G. Pavan Kumar, Chaitanya Mulakayala, Chitta Suresh Kumar,Arunasree M. Kalle, M.V. Basaveswara Rao, Srinivas Oruganti, Manojit Pal*
O
O
O
O
HN
Alkyl/(Het)aryl
COX-2X-ray
Part II. Development of novel colchicine-derived immunosuppressants with improved pharmacokineticproperties
pp 6750–6755
Dong-Jo Chang*, Sujin Lee, Jaebong Jang, Soon-Ok Kim, Wan-Joo Kim, Young-Ger Suh*
O
OO
NH
O
O
14, MLR IC50: 5 nM, F: 67.3 %SMe
Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539 6537
Optimisation of pharmacokinetic properties in a neutral series of 11b-HSD1 inhibitors pp 6756–6761
James S. Scott*, Adrian L. Gill, Linda Godfrey, Sam D. Groombridge, Amanda Rees, John Revill, Paul Schofield, Pernilla Sörme,Andrew Stocker, John G. Swales, Paul R.O. Whittamore
Human 11β-HSD IC50 7 nM Human 11β-HSD IC50 102 nM Mouse 11β-HSD IC50 922 nM Mouse 11β-HSD IC50 95 nM Rat Bioavailability 11% Rat Bioavailability 100%
Dog Bioavailability 100%
S
NH
N
OOH
NH
N
N
OOH
NO1 25
Evaluation of structure-derived pharmacophore of soluble epoxide hydrolase inhibitors by virtualscreening
4-Substituted-2-phenylquinazolines as inhibitors of BCRP pp 6766–6769
Kapil Juvale, Michael Wiese*
N
N
HNN
NN N
R
1-17 18-24
R
Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors ofhistone deacetylases
pp 6770–6772
Md. Ashraful Hoque, Toru Arai, Norikazu Nishino*, Hyun-Jung Kim, Akihiro Ito, Minoru Yoshida
6538 Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539
OTHER CONTENTS
Corrigenda pp 6773–6775
*Corresponding authorSupplementary data available via SciVerse ScienceDirect
COVER
Molecular recognition of protein targets by organic molecules is influenced by three-dimensional shape complementarity. As illustrated in thecover photograph, increasingly complex binding pockets may be better approached with small molecules possessing structural complexity inthe chemical core and diversity in appending groups. Products of diversity-oriented synthesis (DOS) possess these attributes, and may befurther biased toward specific protein families by appending reactive functional groups. Recently, Schreiber and colleagues reported thedevelopment of potent, selective inhibitors of histone deacetylase isoforms by biasing DOS macrocycles using metal-binding chemical features(Bioorg Med Chem Lett. 2011 May 1;21(9):2601-5). This strategy may be applicable to many other targets of interest in ligand discovery.Photograph by Richard Oakley and James Bradner (Dana-Farber Cancer Institute, Boston, MA).
Available online at www.sciencedirect.com
Indexed/Abstracted in: Beilstein, Biochemistry & Biophysics Citation Index, CANCERLIT, Chemical Abstracts, ChemistryCitation Index, Current Awareness in Biological Sciences/BIOBASE, Current Contents: Life Sciences, EMBASE/Excerpta Medica,MEDLINE, PASCAL, Research Alert, Science Citation Index, SciSearch, TOXFILE. Also covered in the abstract and citationdatabase SciVerse Scopus�. Full text available on SciVerse ScienceDirect�
ISSN 0960-894X
Contents / Bioorg. Med. Chem. Lett. 22 (2012) 6527–6539 6539
![FLAMING CLIFFS 2 - [FLAMING CLIFFS 2] 1 TABLE OF CONTENTS | GRAPHICAL USER INTERFACE TABLE OF CONTENTS MAIN MENU .....4 ...](https://static.documents.pub/doc/80x56/5af425d67f8b9ae9488ba3f5/flaming-cliffs-2-flaming-cliffs-2-1-table-of-contents-graphical-user-interface.jpg)
